BenevolentAI Investor Conference Presentation Deck
BEN-8744
Ulcerative Colitis (UC)
Affects 0.4% US population), 1.7
million patients in 7MM), forecast
$7.8bn market by 2026(2)
• A chronic, lifelong disease that causes inflammation
and ulceration of the inner lining of the colon and
rectum
• 64% of patients are mild-moderate, 31% of patients are
moderate-severe and 5% of patients are
severe-fulminant
• Efficacy - 20-40% of Moderate-severe patients do not
respond to anti-TNF (main treatment paradigm) (3)
• Safety - Treatments have many side effects - from
steroids to anti-TNF and JAK inhibitors (black box
warnings) (4)
• High unmet need for an alternative oral small molecule
treatment option with improved safety profile and
efficacy in treatment of refractory patients
●
●
BEN-8744: Oral, peripherally-restricted,
PDE10 inhibitor under development as a
first-in-class treatment for refractory UC
Phosphodiesterase 10 (PDE10) was identified by our
TargetID platform as an entirely novel target for the
treatment of UC/IBD
Using our Molecular Design expertise we optimally
designed a best in class peripherally restricted PDE10
inhibitor: BEN-8744
• BEN-8744 is expected to provide an efficacious
disease modifying oral treatment for UC/IBD
• BEN-8744 will target Moderate and Severe UC/IBD
patients, meeting the unmet need left by existing
therapies including:
o Patients refractory to anti-TNFS or other biologics
o Improved safety and tolerability profile compared
to competitors
o Aiming to use a Precision Medicine approach to
target key responder patient cohorts and avoid the
safety risks associated with ineffective therapies
Sources: (1) GlobalData: Ulcerative Colitis, Global Drug Forecast and Market Analysis to 2026; (2) Evaluate Pharma: Gastro-intestinal,
Inflammatory bowel disease (IBD), Ulcerative colitis, Worldwide Overview (report 17th Sep 2021); (3) Roda et al. Clin Transl Gastroenterol 2016;
(4) Kobayashi et al Nat Rev Dis Primers 2020 and US FDA Drug Safety Communication 2021
Benevolent 21View entire presentation